Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges

doi:10.4254/wjh.v16.i5.731

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1060)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

839

Figures (1-2)

Tables (1-2)

Sum=973

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=22

May 27, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. May 27, 2024; 16(5): 731-750
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.731

Full Size Figure Download Figure

Figure 2 A simplified schematic illustrating how glucagon acts on multiple organs to mitigate metabolic dysfunction-associated steatotic liver disease.

Citation: Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World J Hepatol 2024; 16(5): 731-750
URL: https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i5.731